The FDA has approved Flow Neuroscience’s FL-100, the first prescription at-home brain-stimulation device for major depressive disorder, bringing supervised tDCS into US clinical care.

ARPA-H has launched EVIDENT, a $100M program to build quantitative measurement systems and data infrastructure for mental health, linking rapid-acting treatments to objective, longitudinal clinical evidence.

Beacon Biosignals secured $86M in Series B funding and expanded its Takeda collaboration, positioning at-home EEG and sleep data as a scalable biomarker layer inside CNS drug development.

INBRAIN has teamed up with Microsoft to combine graphene BCIs with agentic AI on Azure, aiming to build adaptive, closed-loop neurotherapies that learn from each patient’s brain signals in real time.

NextSense has raised a $16M Series A to commercialize in-ear EEG Smartbuds, bringing direct brain-based sleep tracking and adaptive audio into a familiar consumer earbud form factor.

UNESCO has adopted the first global neurotechnology ethics standard, treating neural data as sensitive, banning sleep-based manipulation, and setting strict limits for workplace and classroom use as neurotech enters consumer products.

Nike’s new Mind shoes apply sensory stimulation through the foot to influence focus, signaling a major consumer brand’s entry into neuro-influenced product design.

Neuralink’s first UK implant shows its intracortical BCI can be deployed inside the NHS with rapid, functional control.

The PRIMA retinal implant demonstrates clinically validated restoration of functional vision in advanced macular degeneration, marking a major milestone for sensory BCIs.

Alto Neuroscience has raised $50 million and aligned with the FDA to accelerate its depression program, positioning biomarker-guided patient selection as a practical tool for late-stage psychiatric drug development.

A university hospital in Munich has completed Europe’s first intracortical BCI implant in a patient with quadriplegia, reflecting a clinic-first model focused on safety, rehabilitation, and healthcare-system readiness rather than speed or publicity.

Neuralink has leased a large life-science facility in South San Francisco, signaling a renewed Bay Area presence as the company moves from early human trials toward clinical scale-up and operational maturity.

As neurotechnology moves into consumer markets, U.S. lawmakers are proposing new protections for brain-derived data, signaling a shift in how neural signals are treated under privacy law.

Neural interfaces are moving from labs into consumer devices. With a wrist-worn EMG band, Meta is testing whether neural intent can become a practical input layer for everyday digital interaction.

Graphene-based brain–computer interfaces are moving out of the lab and into U.S. clinical pathways, as INBRAIN partners with Mayo Clinic to validate a new materials-driven approach to neuromodulation.

A new entrant is forming in the brain–computer interface space with unusually deep capital, strong AI ties, and ambitions that may extend beyond medicine, adding a fresh dynamic to an already competitive neurotech field.

China is moving to industrialise brain–computer interfaces at a national scale, combining state funding, coordinated regulation, and parallel clinical development in an effort to compete with U.S.-led neurotech ecosystems.